Genmab: Darzalex approved in Japan
(CercleFinance.com) - Danish biotech Genmab announced on Thursday that it has obtained approval from the Japanese health authorities for the marketing of its anti-cancer drug Darzalex for the treatment of multiple myeloma, a form of blood cancer.
Genmab says that this approval will trigger a 7 million dollar milestone payment from Janssen, the Johnson & Johnson subsidiary with which Genmab entered into a licensing agreement in 2012.
Under the terms of the partnership, Genmab entrusted Janssen with exclusive worldwide rights to develop, manufacture and distribute the drug.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Genmab says that this approval will trigger a 7 million dollar milestone payment from Janssen, the Johnson & Johnson subsidiary with which Genmab entered into a licensing agreement in 2012.
Under the terms of the partnership, Genmab entrusted Janssen with exclusive worldwide rights to develop, manufacture and distribute the drug.
Copyright (c) 2019 CercleFinance.com. All rights reserved.